Equillium Q2 EPS $(0.04) Beats $(0.05) Estimate

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings

8-K filing — Equillium, Inc. (EQ)

Filed: 2026-10-26 AccNo: 0001193125-26-432158 Size: 181 KB Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

Equillium, Inc. has initiated its Phase 1 clinical trial for EQ504, an investigational oral, colon-targeted aryl hydrocarbon receptor (AhR) modulator, by dosing the first subject in Australia.

Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6

Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.

Australia's Therapeutic Goods Administration Grants Equillium Human Research Ethics Committee Approval For Phase 1 Clinical Trial Of EQ504.

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.